Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7582656 | 1.00 | GPR84 (0.44) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL5718514 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL7652872 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL27745640 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL27575401 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL453154 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL712622 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL28253693 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL8935618 | 0.87 | HCAR2 (0.48) | GPR84FFAR1HCAR2PLA2G4BNAAA | |
| SCHEMBL3960625 | 0.85 | HCAR2 (0.47) | GPR84FFAR1HCAR2PLA2G4BNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | GPR84 645/4885FFAR1 52/4885HCAR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.